3-V Biosciences, a Menlo Park, Calif.-based biopharmaceutical company, closed $28.5m in Series D funding.
The round was led by New Enterprise Associates, Kleiner Perkins Caufield & Byers and Rock Springs Capital Management with participation from new investor Ally Bridge Group.
Led by Merdad Parsey, M.D., Ph.D, Chief Executive Officer, 3-V Biosciences is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company’s lead candidate is TVB-2640, an oral, proprietary fatty acid synthase (FASN) inhibitor being evaluated for the treatment of solid tumors.
3-V intends to use the funds to advance its oncology clinical trials being performed as monotherapy and in combination with cytotoxic agents through phase IB expansion cohorts. In addition, it expects to conclude preclinical and IND-enabling work for the second program derived from their drug-discovery platform for regulatory (IND or CT) filing in 2015.